Results 161 to 170 of about 791,647 (284)

Pulmonary vein stenosis due to pulmonary lymphoma in a cat. [PDF]

open access: yesJ Vet Med Sci
Morita T   +4 more
europepmc   +1 more source

A retrospective study on the clinical characteristics and radiological features of primary pulmonary lymphoma. [PDF]

open access: yesTransl Cancer Res, 2020
Xie X   +7 more
europepmc   +1 more source

The Lymphoma Information Network

open access: yes
The Lymphoma Information Network website strives to "put a bit of humanity and understanding to this disease, to gather lymphoma information and resources in one place, and to present information in an easy to understand and logical format." ...

core  

Comorbid conditions after allogeneic haematopoietic stem cell transplantation in young adults in Germany—A prospective, multicentre trial

open access: yesBritish Journal of Haematology, EarlyView.
Summary Young adults (YA) are particularly affected by comorbid conditions following allogeneic haematopoietic stem cell transplantation (alloHSCT), as they have to live with them for many years. This is the first multicentre prospective study investigating sequelae after alloHSCT in YA in Germany. In total, 107 patients who survived relapse‐free until
Pauline Rocke   +9 more
wiley   +1 more source

Comparison of radiologic characteristics and pathological presentations of primary pulmonary lymphoma in 22 patients. [PDF]

open access: yesJ Int Med Res, 2020
Wang Y   +11 more
europepmc   +1 more source

Primary Pulmonary Lymphoma

open access: yesTurkiye Klinikleri Archives of Lung, 2023
Ayberk Kaan BOYACIOĞLU   +6 more
openaire   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy